Y2024
AL101-AMD Clinical Phase 3 IND Approved for Wet Macular Degeneration Treatment

Y2023
Technology transfer of AL101-AMD, a treatment for wet macular degeneration (Hallym Pharmaceutical/Sangmyung Innovation)
Completed Phase 2a clinical trial for AL101-OME, a treatment for otitis media with effusion

Y2022
Completed Phase 2 clinical trial for AL101-AMD, a treatment for wet macular degeneration
Completed Phase 2a clinical trial for AL101-MASH, a treatment for metabolic syndrome-related fatty liver disease
Completed Phase 2 clinical trial for AL102-PDT, a treatment for periodontal disease
Development of an antibody conjugated with a photosensitizer (APC) through joint research with external institutions (selected for a project by the Ministry of SMEs and Startups)

Y2019 ~ Y2021
V.C. funding 8.5 billion KRW

Y2019
Signed a MOU on PASylation technology with XL-protein
Received the Korea Industry Grand Prize in Biotechnology Award from Money Today
Received the Korea KONEX Award for Best Technology by the Korea Exchange

Y2018
Launched sales of Ob-X on home-shopping channels

Y2016
Listed in KONEX

Y2013 ~ Y2016
V.C. funding 12 billion KRW

Y2015
AL101-AMD Phase 2 IND approved

Y2012
Started sales of Ob-X in Korea and overseas

Y2010
Ob-X approved as a functional ingredient with health claim by MFDS

Y2009
Completed Phase 2 clinical trial of AL101-AOB for abdominal obesity

Y2007
Awarded INNO-BIZ certification by the SMBA (Small and Medium Business Administration)

Y2006
Attracted capital from the KDB (Korea Development Bank) for technology development

Y2005
Selected as an 'Excellent Company' by the Korea Technology and Credit Guarantee Agency

Y2004 ~ Y2009
Awarded numerous research grants from the Ministry of Health & Welfare and the SMBA for developing new drugs

Y2000
Research center was certified

Y1999
Recognized as a start-up with good technology